Claritas Pharmaceuticals, Inc. announced that it has signed a Letter of Intent dated January 17, 2022 with Salzman Group, Inc. Salzman Group Ltd. and Salzman Group Pty. Ltd. (collectively, the "Salzman Group"), under which Salzman Group will grant to Claritas an exclusive, worldwide license to develop and commercialize R-107 for the treatment of skin ulceration and wound healing, including the treatment of severe burns. R-107 is a liquid, nitric oxide-releasing molecule with issued and pending composition of matter and method of use patents in approximately 40 countries, including the U.S., Australia, Brazil, China, Europe, India, Japan, Russia and South Korea. Claritas previously licensed R-107 from Salzman Group for the treatment of both COVID-related lung disease and non-COVID pulmonary diseases. In accordance with the LOI, and subject to the approval of the TSX Venture Exchange, Claritas will enter into a new license agreement with Salzman Group for the development and commercialization of R-107 for the treatment of skin ulceration and wound healing, including the treatment of severe burns (the "License"). The Company expects to enter into the License
by mid-February 2022.